Bosentan Ameliorated Exercise-Induced Pulmonary Arterial Hypertension Complicated with Systemic Sclerosis
Bosentan Ameliorated Exercise-Induced Pulmonary Arterial Hypertension Complicated with Systemic Sclerosis
复制标题
DOI：
10.2169/internalmedicine.49.3812
复制
发表时间：
2010-01-01
影响因子：
1.2
通讯作者：
Sata, Masataka
中科院分区：
文献类型：
--
作者：
Yagi, Shusuke;Akaike, Masashi;Sata, Masataka
肺动脉高压（PAH）是系统性硬化症患者的常见并发症。波生坦用于有症状的PAH患者;然而，尚未确定波生坦是否能改善无PAH相关症状患者的PAH进展。我们介绍了一例无PAH相关症状的系统性硬化症患者，通过6分钟步行负荷超声心动图、肱动脉血流介导的扩张和手足皮肤温度评估，波生坦改善了运动诱导的PAH。结果表明，波生坦治疗早期PAH患者可通过改善内皮功能改善肺动脉血管舒张。
Pulmonary arterial hypertension (PAH) is a frequent complication in patients with systemic sclerosis. Bosentan is used in patients with symptomatic PAH; however, it has not been established whether or not bosentan ameliorates the progression of PAH in patients with no PAH-related symptoms.We present a case of systemic sclerosis with no PAH-related symptoms in which bosentan ameliorated exercise-induced PAH evaluated by 6-minute walk stress echocardiography, brachial flow-mediated dilation, and skin temperature of hands and feet. The results suggest that administration of bosentan in patients with early-stage PAH ameliorates pulmonary arterial vasodilatation through improvement of endothelial function.